# DuplexSeq

Type: Technology

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/duplexseq
Canonical HTML page: https://getbiobrief.com/entity/duplexseq

## Timeline

- **2026-Q2**: Integration Phase — Transfer of DuplexSeq equipment and IP to Scantox facilities and staff training.
- **2026-02-26**: Acquisition Announced — Scantox officially announces the purchase of TwinStrand's nonclinical genomics safety business.
- **2026**: Full Commercial Launch — Scantox expected to offer full-scale DuplexSeq services as part of its standard safety assessment packages.

## Recent coverage (1 stories)

### Scantox Bolsters Genetic Tox Portfolio with TwinStrand’s DuplexSeq Acquisition
2026-02-26 11:32:04 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Scantox has acquired the DuplexSeq™ nonclinical genomics safety business from TwinStrand Biosciences, integrating ultra-sensitive sequencing technology into its pre-clinical service suite. This strategic move positions Scantox as a leader in high-resolution genetic toxicology, offering pharmaceutical clients unprecedented accuracy in identifying mutagenic risks.
Full story: https://getbiobrief.com/story/scantox-acquires-twinstrand-duplexseq-genomics

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.